These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 34769517)

  • 21. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
    Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
    Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
    Sharma N; Rao SP; Kalivendi SV
    Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
    Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
    JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The central theme of Parkinson's disease: α-synuclein.
    Ozansoy M; Başak AN
    Mol Neurobiol; 2013 Apr; 47(2):460-5. PubMed ID: 23180276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Parkinson disease protein α-synuclein inhibits autophagy.
    Winslow AR; Rubinsztein DC
    Autophagy; 2011 Apr; 7(4):429-31. PubMed ID: 21157184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of the endolysosomal system in Parkinson's disease.
    Vidyadhara DJ; Lee JE; Chandra SS
    J Neurochem; 2019 Sep; 150(5):487-506. PubMed ID: 31287913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Golgi fragmentation is Rab and SNARE dependent in cellular models of Parkinson's disease.
    Rendón WO; Martínez-Alonso E; Tomás M; Martínez-Martínez N; Martínez-Menárguez JA
    Histochem Cell Biol; 2013 May; 139(5):671-84. PubMed ID: 23212845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
    Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
    Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.
    Jeong GR; Jang EH; Bae JR; Jun S; Kang HC; Park CH; Shin JH; Yamamoto Y; Tanaka-Yamamoto K; Dawson VL; Dawson TM; Hur EM; Lee BD
    Mol Neurodegener; 2018 Feb; 13(1):8. PubMed ID: 29439717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease.
    Lin KJ; Lin KL; Chen SD; Liou CW; Chuang YC; Lin HY; Lin TK
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LRRK2 pathobiology in Parkinson's disease.
    Martin I; Kim JW; Dawson VL; Dawson TM
    J Neurochem; 2014 Dec; 131(5):554-65. PubMed ID: 25251388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell death pathways in Parkinson's disease: role of mitochondria.
    Yao Z; Wood NW
    Antioxid Redox Signal; 2009 Sep; 11(9):2135-49. PubMed ID: 19422283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current perspective of mitochondrial biology in Parkinson's disease.
    Ammal Kaidery N; Thomas B
    Neurochem Int; 2018 Jul; 117():91-113. PubMed ID: 29550604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitochondrial dysfunction in genetic animal models of Parkinson's disease.
    Trancikova A; Tsika E; Moore DJ
    Antioxid Redox Signal; 2012 May; 16(9):896-919. PubMed ID: 21848447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis.
    Gitler AD; Bevis BJ; Shorter J; Strathearn KE; Hamamichi S; Su LJ; Caldwell KA; Caldwell GA; Rochet JC; McCaffery JM; Barlowe C; Lindquist S
    Proc Natl Acad Sci U S A; 2008 Jan; 105(1):145-50. PubMed ID: 18162536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.